Dianthus Therapeutics Inc. (DNTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.98 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Dianthus Therapeutics Inc. market capitalisation for the company's overall valuation and market capitalisation.
Dianthus Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Dianthus Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dianthus Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dianthus Therapeutics Inc. ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Dianthus Therapeutics Inc. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Landstar System Inc
NASDAQ:LSTR
|
-0.060x |
|
Fortnox AB
ST:FNOX
|
0.058x |
|
China Coal Energy Company Limited
F:CVV
|
0.030x |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
0.003x |
|
Compagnie du Cambodge
PA:CBDG
|
0.004x |
|
Codan Ltd
AU:CDA
|
0.097x |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
-0.103x |
|
Railway Signal Communication Ltd
SHG:688009
|
0.013x |
Annual Cash Flow Conversion Efficiency for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Dianthus Therapeutics Inc. from 2016 to 2025. View Dianthus Therapeutics Inc. (DNTH) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $493.40 Million | $-129.06 Million | -0.262x | -17.93% |
| 2024-12-31 | $352.48 Million | $-78.18 Million | -0.222x | -1.61% |
| 2023-12-31 | $168.87 Million | $-36.86 Million | -0.218x | +44.69% |
| 2022-12-31 | $73.66 Million | $-29.07 Million | -0.395x | -14.48% |
| 2021-12-31 | $172.67 Million | $-59.53 Million | -0.345x | +22.51% |
| 2020-12-31 | $143.91 Million | $-64.02 Million | -0.445x | -10.00% |
| 2019-12-31 | $141.19 Million | $-57.10 Million | -0.404x | -40.63% |
| 2018-12-31 | $145.65 Million | $-41.89 Million | -0.288x | +35.00% |
| 2017-12-31 | $50.32 Million | $-22.26 Million | -0.442x | +38.73% |
| 2016-12-31 | $9.04 Million | $-6.53 Million | -0.722x | -- |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more